Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
8 search results for:

Ponatinib 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 03-07-2016 | Chronic myeloid leukemia | News | Article

    First year of ponatinib response predicts 3-year CML survival

    An early, deep molecular response to ponatinib is a significant predictor of overall survival and progression-free survival in heavily pretreated patients with chronic myeloid leukaemia in the chronic phase, research suggests.

    Published in:
    European Hematology Association 21 st Congress; Copenhagen, Denmark: 9–12 June 2016
  2. 02-02-2018 | Chronic myeloid leukemia | Editorial | Article

    Discontinuing tyrosine kinase inhibitors in chronic myeloid leukemia

    Several other TKIs are currently FDA-approved for the therapy of patients with CML: nilotinib [8], dasatinib [9], bosutinib [10] and ponatinib [11].

    Author:
    Ehab Atallah MD
  3. 02-02-2018 | Chronic myeloid leukemia | Highlight | Teaser
    Expert opinion

    Discontinuing tyrosine kinase inhibitors in chronic myeloid leukemia

    Tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) can result in prolonged and deep responses in many patients. In such cases, can TKIs be safely discontinued to avoid adverse side effects and costs? Etab Atallah (Medical College of Wisconsin, USA) discusses the current issues surrounding TKI discontinuation in CML.

  4. 18-10-2016 | Bcr-Abl tyrosine kinase inhibitors | ReviewPaper | Article

    Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?

    Ponatinib.  

    Author:
    Gianantonio Rosti, Fausto Castagnetti, Gabriele Gugliotta, Michele Baccarani
  5. 03-06-2016 | Chronic myeloid leukemia | Article

    European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

    In any Rutherford stage, ponatinib is not advisable, and nilotinib is not advisable if prior PAOD is severe.

    Author:
    J L Steegmann, M Baccarani, M Breccia, L F Casado, V García-Gutiérrez, A Hochhaus, D-W Kim, T D Kim, H J Khoury, P Le Coutre, J Mayer, D Milojkovic, K Porkka, D Rea, G Rosti, S Saussele, R Hehlmann, R E Clark
  6. 14-03-2017 | Leukemia | Editorial | Article

    FMS-like tyrosine kinase 3 (FLT3)-inhibition in FLT3 mutated acute myeloid leukemia: A promising approach

    Ponatinib, approved as a BCR-ABL inhibitor, is a multikinase inhibitor.

    Author:
    Xavier Thomas MD
  7. 15-11-2016 | Acute lymphoblastic leukemia | Book chapter | Article

    Therapeutic management of acute lymphoblastic leukemia

    First- (imatinib) and second-generation tyrosine kinase inhibitors (TKIs; nilotinib, dasatinib, bosutinib, and ponatinib) are available and their optimal use in BCR-ABL + ALL is under intensive investigation.

    Author:
    Karsten Spiekermann
  8. 17-11-2015 | Hematologic cancers | Article

    Allogeneic transplantation for CML in the TKI era: striking the right balance

    The third-generation drug, ponatinib, has shown impressive efficacy as a second, third and fourth-line therapy 59 ; once again, those patients who are likely to respond well to ponatinib can be identified after 3 months of treatment.

    Author:
    Andrew J. Innes, Dragana Milojkovic, Jane F. Apperley
  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.